PubMed

Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.

Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, Parving HH, Cooper ME, Shahinfar S, Brenner BM.

Diabetes Care. 2008 Mar;31(3):445-7. Epub 2007 Dec 10.PMID: 18070995 [PubMed - indexed for MEDLINE]Related articlesFree article

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Kidney Int. 2004 Jun;65(6):2309-20.PMID: 15149345 [PubMed - indexed for MEDLINE]Related articles

Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.

Gerth WC, Remuzzi G, Viberti G, Hannedouche T, Martinez-Castelao A, Shahinfar S, Carides GW, Brenner B.

Kidney Int Suppl. 2002 Dec;(82):S68-72.PMID: 12410859 [PubMed - indexed for MEDLINE]Related articles

Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.

Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, Brenner BM; RENAAL Investigators.

Kidney Int Suppl. 2002 Dec;(82):S64-7.PMID: 12410858 [PubMed - indexed for MEDLINE]Related articles

Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.

J Am Soc Nephrol. 2007 May;18(5):1540-6. Epub 2007 Apr 4.PMID: 17409317 [PubMed - indexed for MEDLINE]Related articlesFree article

Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.

Alexander CM, Lyle PA, Keane WF, Carides GW, Zhang Z, Shahinfar S.

Kidney Int Suppl. 2004 Nov;(92):S115-7. Review.PMID: 15485403 [PubMed - indexed for MEDLINE]Related articles

Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.

de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S.

Kidney Int. 2006 May;69(9):1675-82.PMID: 16572114 [PubMed - indexed for MEDLINE]Related articles

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.

Chan JC, Wat NM, So WY, Lam KS, Chua CT, Wong KS, Morad Z, Dickson TZ, Hille D, Zhang Z, Cooper ME, Shahinfar S, Brenner BM, Kurokawa K; Asian RENAAL Study Investigators.

Diabetes Care. 2004 Apr;27(4):874-9.PMID: 15047641 [PubMed - indexed for MEDLINE]Related articlesFree article

Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.

Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.

Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S22-5. Review.PMID: 12612946 [PubMed - indexed for MEDLINE]Related articles

Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.

Ruilope LM, Segura J.

Clin Ther. 2003 Dec;25(12):3044-64. Review.PMID: 14749145 [PubMed - indexed for MEDLINE]Related articles

Losartan and end-organ protection--lessons from the RENAAL study.

Kowey PR, Dickson TZ, Zhang Z, Shahinfar S, Brenner BM; RENAAL Investigators.

Clin Cardiol. 2005 Mar;28(3):136-42.PMID: 15813620 [PubMed - indexed for MEDLINE]Related articles

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.

Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group.

Arch Intern Med. 2003 Jul 14;163(13):1555-65.PMID: 12860578 [PubMed - indexed for MEDLINE]Related articlesFree article

Analysis of metabolic parameters as predictors of risk in the RENAAL study.

Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S, Brenner BM; RENAAL Study.

Diabetes Care. 2003 May;26(5):1402-7.PMID: 12716796 [PubMed - indexed for MEDLINE]Related articlesFree article

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.

Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z.

Clin Exp Nephrol. 2006 Sep;10(3):193-200.PMID: 17009077 [PubMed - indexed for MEDLINE]Related articles

Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.

Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM; RENAAL Study Group.

J Am Soc Nephrol. 2004 Dec;15(12):3117-25.PMID: 15579515 [PubMed - indexed for MEDLINE]Related articlesFree article

The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.

Szucs TD, Sandoz MS, Keusch GW.

Swiss Med Wkly. 2004 Aug 7;134(31-32):440-7.PMID: 15389347 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.

Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD.

Kidney Int. 2008 Mar;73(5):630-6. Epub 2007 Dec 19.PMID: 18094675 [PubMed - indexed for MEDLINE]Related articles

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators.

N Engl J Med. 2001 Sep 20;345(12):861-9.PMID: 11565518 [PubMed - indexed for MEDLINE]Related articlesFree article

Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM.

J Am Soc Nephrol. 2005 Jun;16(6):1775-80. Epub 2005 May 4.PMID: 15872078 [PubMed - indexed for MEDLINE]Related articlesFree article

Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.

Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I; Canadian Hypertension Society.

Can J Cardiol. 2004 May 1;20(6):613-8.PMID: 15152291 [PubMed - indexed for MEDLINE]Related articlesFree article